NVBDCP

21. • The WHO has recommended artemisinin combination therapies
(ACT) be the first-line therapy for P. falciparum malaria
worldwide.
• As short-acting drugs, artemisinin compounds are given with
one or two long-acting drugs like amodiaquine, mefloquine,
sulfadoxine/pyrimethamine or lumefantrine.
• Combinations are effective because the artemisinin component
kills the majority of parasites at the start of the treatment, while
the more slowly eliminated partner drug clears the remaining
parasites.
• Several fixed-dose ACTs are now available containing an
artemisinin component and a partner drug which has a long
half-life, such as mefloquine (ASMQ),lumefantrine (Coartem),
amodiaquine (ASAQ), piperaquine (Duo-Cotecxin), and
pyronaridine (Pyramax).
• Artemisinins are not used for malaria prevention because of the
extremely short activity (half-life) of the drug. To be effective, it
would have to be administered multiple times each day.

22. • Description of the Test Kit
• The Bivalent Rapid Diagnostic Test Kit (RDK) for Malaria
should comprise of test card (cassette)and reagents
including buffer solution in a dropping bottle. The test kit
should be able to conduct the rapid diagnosis for both
P. falciparum and P. vivax.
• The test should be based on the principle of capture
of parasite antigen from blood using monoclonal
antibodies specific for antigen targets. Each test kit
should contain all the material required for conducting
the test including individually packed sterile lancets for
pricking, heparinized capillary tubes (diameter -1 mm)
with relevant markings and reaction tubes with stand /
wells as required.

25. • The main activities of the programme are :
1. Formulating policies and guidelines.
2. Technical guidance.
3. Planning.
4. Logistics.
5. Monitoring and evaluation.
6. Coordination of activities through the States/Union
Territories and in consultation with national organizations
such as National Centre for Disease Control (NCDC),
National Institute of Malaria Research (NIMR).
7. Collaboration with international organizations like the
WHO, World Bank, GFATM and other donor agencies.
8. Training.
9. Facilitating research through NCDC, NIMR, Regional
Medical Research Centres etc.
10. Coordinating control activities in the inter-state and
inter-country border areas.

37. • Annual Blood Examination Rate (A.B.B.R.) = Smears examined in
a year X 100 / Total population.
• Annual Parasitic Incidence (A.P.I.) = Total no. of positive slides
for parasite in a year x 1000 / Total population.
• Annual Falciparum Incidence = Total positive PF in a year x 1000
/ Total population.
• Slide Positivity Rate (S.P.R.) = Total positive x 100 / Total slides
examined.
• Slide Falciparum Rate (S.F.R.) = Total positive PF x 100 / Slides
examined.
• P. falciparum Percentage (PF %) = Total positive for P. falciparum
x 100 / Total positive for MP

58. Objectives

63. IMPACT INDICATORS
• To bring down annual incidence of malaria to less
than 1 per 1000 population at national level by
2017
• At least 50% reduction in mortality due to malaria
by the year 2017

64. Strategies
• Reform approaches to program planning and
management
• Improve and enhance surveillance and strengthen
monitoring and evaluation
• Scale up coverage and proper use of insecticide
treated
• Target interventions to risk group
• Scale up control of P.vivax

71. Wuchereria bancrofti,brugia malayi,brugia timori

88. MID TERM PLAN FOR PREVENTION AND
CONTROL OF DENGUE - 2011
• COMPONENTS
• SURVEILLANCE
• CASE MANAGEMENT
• VECTOR MANAGEMENT
• OUT BREAK RESPONSE
• CAPACITY BUILDING
• BCC AND IEC
• INTERSECTORAL COORDINATION
• MONTORING AND SUPERVISION